forum

DIVISLAB Share Price Discussion

Divi's Laboratories Ltd.
Sector: Pharmaceuticals and health care
... Read more
DIVISLAB Share Price *
1,642 +13.65 (0.84%)
* (quote may be delayed)

DIVISLAB Discussion Forum


16-09-19
DIVISLAB SEP CE 1660 (Intraday)
only above @ 29
Like
reply
Reply
share
Share

Levels for Divislab future
Buy abv 1634 for 1636 1638 1640
Sell blw 1626 for 1624 1622 1620
Like
reply
Reply (2)
share
Share
Latest replies

Bang all trgt achieved 👍👍👍👍
High made 1652
Book ur profit or shift sl

New high 1656

divis
postional given at 1650
now made 1610 + 40000
Like
reply
Reply
share
Share

DIVISLAB BUY AT 1620 TGT 1636/1640
Like
reply
Reply
share
Share

Accuracy Maintain calls 1625-1620 SL 1640 Target 1615 , 1610
-ve #negative direction side stocks #SBIN 283 SL 288 Targets 280 , 277 #YesBank 65 Targets 63 #b #India #Marke is #DownTrend will #Fall
Like
reply
Reply
share
Share

DIVISLAB - chart - 355364
The Ichimoku Cloud is a collection of technical indicators that show support and resistance levels, as well as momentum and trend direction.
Tenkan-Sen (Green Line), or Conversion Line, is the mid-point of the highest and lowest prices of an asset over the last nine periods. The...
Read more...
Like
reply
Reply (1)
share
Share
Latest replies
Chetan Patil @chetanpatil
Sep 13 1:59 AM

Sir why are you writing the same junk in every post? kya aap baki logo ki tarah chart explain nahi kar sate ? Kisi bhi language me?
Top 10 high-conviction buying ideas from brokerage firms in a volatile market
Corporate banks, insurance, healthcare services, oil and gas, construction, engineering and logistics are among the key overweight sectors.
Moneycontrol
Like
reply
Reply
share
Share

divislab
1650 to 1625 + 25000
derisk n hold
chapo india chapo
Like
reply
Reply
share
Share

RISKY OPTION CALL
******************
STOCK: DIVISLAB 1660 CE @ 39.55
STOP LOSS: YOURS
TARGET: 45.00
LOT SIZE: 400
Like
reply
Reply (1)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Sep 5 8:09 PM

40.75

divis 1635. divis 1635
Like
reply
Reply (1)
share
Share
Latest replies
Calls Unlimited @calls
Sep 4 8:13 PM

sl hit

Buy Divis Lab @1640 SL 1620 , Targets1655 , 1670 , 1715
BuyNifty above 10800 SL10700
Targets 10850 , 10950 , 11000
Buy Bank Nifty above 26800
SL 26500 Targets 27100
Like
reply
Reply
share
Share

DIVISLAB - 340518
#Hello #Asian ( #Japan #China #India ) #Investors
#World #MARKET is #MOVING on the #TOP so #INVEST for #LongTerm
Like
reply
Reply
share
Share

DIVISLAB - chart - 339485
# DIVISLAB OVERVIEW
Like
reply
Reply
share
Share
Stocks in the news: Tata Motors, Maruti Suzuki, SPML Infra, PNB, Canara Bank
Karnataka Bank | PNB | Divis Lab | JSW Steel | M&M and Coffee Day Enterprises are the stocks, which are in news today.
Moneycontrol
Like
reply
Reply
share
Share

DIVISLAB - 336762

Like
reply
Reply
share
Share

DIVISLAB NSE CASH SELL BELOW 1600, FOR TARGET 1590 - 1580
CMP 1603
Like
reply
Reply
share
Share

Invest in Divis Lab 1605 - 1610 for long term SL 1580 Targets 1645 , 1695 , 1745
इन सारे स्टॉक्स में लंबे समय के लिये निवेश करे।
#Hello #Indian #Traders #invest in #UPL #BajajFinance ,
#PNB #SBIN , #AsianPaints #SunTeck reality #Prestige #PowerGrid , #TataGlobal , #BEML , #HCLte...
Read more...
Like
reply
Reply
share
Share

Invest in DivisLab 1605-1615 for long term SL 1580 Targets 1645 , 1695 , 1745
इन सारे स्टॉक्स में लंबे समय के लिये निवेश करे।
#Hello #Indian #Traders #invest in #UPL #BajajFinance ,
#PNB #SBIN , #AsianPaints #SunTeck reality #Prestige #PowerGrid , #TataGlobal , #BEML , #HCLtech ...
Read more...
Like
reply
Reply
share
Share

Investvin Divis Lab 1505 for Long Term SL 1480 Targets 1555 , 1625 , 1645
इन सारे स्टॉक्स में लंबे समय के लिये निवेश करे।
#Hello #Indian #Traders #invest in #UPL #BajajFinance ,
#PNB #SBIN , #AsianPaints #SunTeck reality #Prestige #PowerGrid , #TataGlobal , #BEML , #HCLtech , #D...
Read more...
Like
reply
Reply
share
Share

इन सारे स्टॉक्स में लंबे समय के लिये निवेश करे।
#Hello #Indian #Traders #invest in #UPL #BajajFinance ,
#PNB #SBIN , #AsianPaints #SunTeck reality #Prestige #PowerGrid , #TataGlobal , #BEML , #HCLtech , #DivisLab #PI ind. #TCS for #LongTerm
Like
reply
Reply
share
Share

Buy divislab cmp 1604-1602 Sl 1585 tgt 1615-1630-1650
Like
reply
Reply (2)
share
Share
Latest replies
Pyramidstock @pyramidstock
Aug 29 9:05 PM

FROM 1602 TO 1640 MORE COMING TOMORROW
Pyramidstock @pyramidstock
Aug 30 8:53 PM

FROM 1602 TO 1646+ NOW ENJOY GUYS MORE UPMOVE COMING

DIVISLAB - 327482
#Hello #Indian #Traders #invest in #DivisLab ,
#PNB #SBIN , #BEML , AsianPaints
#SunTeck reality for #LongTerm
Like
reply
Reply
share
Share

buy divislab cmp 1610 Sl 1588 tgt 1625-1640-1660+
Like
reply
Reply (1)
share
Share
Latest replies
Pyramidstock @pyramidstock
Aug 26 8:53 PM

from 1610 to 1619+ More coming enjoy guys
Stocks in the news: Adani Ports, Alkem Lab, Cupid, NCL Industries, Lakshmi Vilas Bank
Dynamatic Technologies | Bandhan Bank | Ipca Laboratories | Indiabulls housing Finance | Piramal Enterprises and DHFL are stocks, which are in news today.
Moneycontrol
Like
reply
Reply
share
Share
Trade Setup for Monday: Top 15 things to know before Opening Bell
The Sensex was up 228.23 points at 36,701.16, while Nifty was up 88.00 points at 10,829.40.
Moneycontrol
Like
reply
Reply
share
Share
'Another 5-8% correction still overdue, but HUL, Kotak Bank, HDFC, Nestle can reach new highs'
It should be on priority to add stocks which are beaten down with blue-chip status, visible earnings, good track record and future growth and of course clean books to be added at the present level, Mustafa Nadeem says
Moneycontrol
Like
reply
Reply
share
Share
Watch out! Top 10 stocks brokerages downgraded post June quarter
Of 114 companies it covers, 36 percent of companies' earnings were below expectations, 15 percent were in-line and 49 percent were above estimates, CLSA said.
Moneycontrol
Like
reply
Reply
share
Share
Rupee at 8-month low; here are 10 stocks that could benefit from the fall in INR
A feeble rupee is not a good sign for the market as it indicates that foreign investors are bearish on the market and exiting their positions
Moneycontrol
Like
reply
Reply
share
Share
Buy Divi’s Laboratories; target of Rs 1800: Sharekhan
Sharekhan is bullish on Divi’s Laboratories has recommended buy rating on the stock with a target price of Rs 1800 in its research report dated August 14, 2019.
Moneycontrol
Like
reply
Reply
share
Share

DIVISLAB - chart - 315535
Divislab
Like
reply
Reply
share
Share
Top 10 stocks that rose or fell in the week
The S&P BSE Midcap index shed 1.31 percent, Smallcap Index was down 0.90 percent and S&P BSE Largecap Index fell 0.59 percent last week.
www.moneycontrol.com
Like
reply
Reply
share
Share

DIVISLAB - 314282

Like
reply
Reply
share
Share

DIVISLAB - chart - 314206
Nifty Pharma
see the updated chart
Clear Break down of Bearish H&S Pattern
Sharp Red Candles one after one in 4 days
Top Looser this Week
Glenmark -14.21%
DivisLab -9.37%
Cadila -6.14%
Like
reply
Reply
share
Share

#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1535-1545 ,
SL1515/1530 #Target1590
#PowerGrid 205-210 , SL200
#Targets210 , 215 , 220
#BuyHCLtech 1075-1085
SL1065 , #Targets1095, 1125
#BuyTataGlobal 265-270, SL260
#Targets270, 275 , 280
#BuySBI...
Read more...
Like
reply
Reply
share
Share

DIVISLAB - 313931
#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1535-1545 ,
SL1515/1530 #Target1590
#PowerGrid 205-210 , SL200
#Targets210 , 215 , 220
#BuyHCLtech 1075-1085
SL1065 , #Targets1095, 1125
#BuyTataGlobal 265-270, SL260
#Targets270, 275 , 280
#BuySB...
Read more...
Like
reply
Reply
share
Share

#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1485-1495 ,
SL1460/1450 #Target1590
#BuyTataGlobal 263-266 , SL260
#Targets275 , 280
#PowerGrid 201-204 , SL195
#Targets205 , 210 , 215 , 220
#BuyTCS 2190-2215 , SL2180
#Targets2230 , 2265 , 2315
#...
Read more...
Like
reply
Reply
share
Share

#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1470-1490 ,
SL1460/1450 #Target1590
Like
reply
Reply
share
Share

#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1470-1490 ,
SL1460/1450 #Target1590
#BuyTataGlobal 263-266 , SL260
#Targets275 , 280
#PowerGrid 201-204 , SL195
#Targets205 , 210 , 215 , 220
#BuyTCS 2190-2215 , SL2180
#Targets2230 , 2265 , 2315
#...
Read more...
Like
reply
Reply
share
Share
Divis Labs tanks 9% as HSBC downgrades, cuts price target after Q1 results
HSBC downgraded the stock to hold from buy call and also slashed price to Rs 1,670 from Rs 1,760 after Q1 earnings.
moneycontrol.com
Like
reply
Reply
share
Share
Hold Divi’s Laboratories; target of Rs 1640: ICICI Direct
ICICI Direct recommended hold rating on Divi’s Laboratories with a target price of Rs 1640 in its research report dated August 12, 2019.
moneycontrol.com
Like
reply
Reply
share
Share

#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1550 -1565 ,
SL1530 #Target1675
Like
reply
Reply
share
Share

HI RISKY CAll BUY divislab @1560/- sl 1538 TR open
Like
reply
Reply
share
Share

sell divislab cmp 1515
Like
reply
Reply (1)
share
Share
Latest replies
Ashish Singh @ashishtrader
Aug 13 3:22 PM

DIVISLAB - 309749
profit booked till now
Stocks in the news: RIL, Tata Motors, ONGC, BHEL, BPCL, Sintex Plastics, Varroc Engg, Oil India
Tata Motors | Alembic | Bosch | National Aluminium Company | Unichem Laboratories | ONGC | BHEL | BPCL and Sintex Plastics are among stocks, which are in news today.
moneycontrol.com
Like
reply
Reply
share
Share
Divis Labs Standalone June 2019 Net Sales at Rs 1,139.92 crore, up 14.53% Y-o-Y
moneycontrol.com
Like
reply
Reply
share
Share
Divis Labs Consolidated June 2019 Net Sales at Rs 1,162.88 crore, up 0% Y-o-Y
moneycontrol.com
Like
reply
Reply
share
Share
Divi’s Lab’s Murali Divi was the highest earning pharma promoter-executive in FY19
Murali Divi, the promoter-executive gave himself a generous hike of 46.3 percent taking his remuneration to Rs 58.8 crore, of which around 57.6 crore came through commission.
www.moneycontrol.com
Like
reply
Reply
share
Share

DIVISLAB - 307429
#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1675 , SL1630
#Target1685
Like
reply
Reply
share
Share

DIVISLAB - 306816
#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyUPL @price545-550 ,
SL530 , #Targets555
#BuyTCS 2245-2255 , SL 2230 ,
#Targets2285 , 2315, 2375
#BuyDivisLab @1655-1665 , SL1640
#Target1675
#BuySBIN @price 293.50-296.50
SL 2892 #Targets300, 305, 310
#Bu...
Read more...
Like
reply
Reply
share
Share

DIVISLAB - 306811
#Today #LongTerm #Stock Tips
------------ #BuyBuyBuy --------------
#BuyDivisLab @1655-1665 , SL1640
#Target1675
Like
reply
Reply
share
Share
  • DIVISLAB - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization45,211.44
    Enterprise Value45,212.24
    Price to Earnings33.24
    Price to Book Value6.48
    Return on Capital Employed0.2
    Return on Equity0.15
    Face Value2
    Dividend Yield0.01
  • DIVISLAB Share Price - Technicals

    keyboard_arrow_down
    DIVISLAB - 52 Week High₹1,774.95
    DIVISLAB - 52 Week Low₹1,212.5
  • DIVISLAB - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    19-Aug-19SharekhanBuy1,800
    12-Aug-19Karvy Stock BrokingHold1,744
    28-May-19ICICIdirect.comHold1,780
    4-Feb-19ICICIdirect.comBuy1,800
    5-Dec-18Axis DirectBuy1,600
    View all DIVISLAB - Share Targets - Broker Reports
  • DIVISLAB Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 161618.351659.51615.31644.8
    Sep 13165516551610.051628.35
    Sep 121625165616131645.15
    Sep 1116291638.951606.41616.55
    Sep 916361653.6516171627.15
  • DIVISLAB Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,599.65
    30 Day Moving Average₹1,601.35
    50 Day Moving Average₹1,611.55
    100 Day Moving Average₹1,620.45
    200 Day Moving Average₹1,599.06
  • DIVISLAB - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,8164,023.47-0.05
    Operating Profit1,2521,438.85-0.13
    Profit Before Tax1,2191,388.23-0.12
    Net Income8701,053.27-0.17
  • DIVISLAB - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds6,9735,9600.17
    Total Liabilities1,0678610.24
    Total Assets8,0406,8210.18
  • DIVISLAB - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity7651,148.05-0.33
    Cash from Investing Activity-476-1,134.08-0.58
    Cash from Financing Activity-314-9.3132.73
    Net Cash Flow-254.66-6.36
  • DIVISLAB - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.130.17
    Return on Equity0.150.19
    Return on Capital Employed0.20.26
  • DIVISLAB - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.24
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.13
    3 Year CAGR Growth in Net Income0.03
    3 Yr CAGR Growth - Diluted EPS-0.49
  • DIVISLAB - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.79
    5 Year CAGR Growth in Operating Profit0.52
    5 Year CAGR Growth in EBIDTA0.57
    5 Year CAGR Growth in Net Income0.42
    3 Yr CAGR Growth - Diluted EPS-0.29
  • DIVISLAB Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 9 9:38 PM
    Top 10 high-conviction buying ideas from brokerage firms in a volatile market
    Moneycontrol
    NewsBot
    Sep 3 1:18 PM
    Stocks in the news: Tata Motors, Maruti Suzuki, SPML Infra, PNB, Canara Bank
    Moneycontrol
    NewsBot
    Aug 26 2:03 PM
    Stocks in the news: Adani Ports, Alkem Lab, Cupid, NCL Industries, Lakshmi Vilas Bank
    Moneycontrol
    NewsBot
    Aug 26 12:43 AM
    Trade Setup for Monday: Top 15 things to know before Opening Bell
    Moneycontrol
    NewsBot
    Aug 25 6:13 PM
    'Another 5-8% correction still overdue, but HUL, Kotak Bank, HDFC, Nestle can reach new highs'
    Moneycontrol
    NewsBot
    Aug 23 7:08 PM
    Watch out! Top 10 stocks brokerages downgraded post June quarter
    Moneycontrol
    NewsBot
    Aug 23 3:38 PM
    Rupee at 8-month low; here are 10 stocks that could benefit from the fall in INR
    Moneycontrol
    NewsBot
    Aug 19 9:23 PM
    Buy Divi’s Laboratories; target of Rs 1800: Sharekhan
    Moneycontrol
    NewsBot
    Aug 17 6:58 PM
    Top 10 stocks that rose or fell in the week
    www.moneycontrol.com
    NewsBot
    Aug 13 7:48 PM
    Divis Labs tanks 9% as HSBC downgrades, cuts price target after Q1 results
    moneycontrol.com
  • DIVISLAB - Related Communities

    keyboard_arrow_down
    Share and discuss algorithms, strateg...
    Place for new investors to ask questi...
    Help fellow traders de-stress by shar...
    Share and discuss strategies for tax ...
    Want to know more about an upcoming I...
    MCX:MENTHAOIL
    MCX:CPO
    Purpose: Pool and discuss ideas & sug...
    Sector: Index
    Sector: Finance
  • DIVISLAB - More Information

    keyboard_arrow_down

    Divi's Laboratories Ltd:
    Divi's Laboratories Limited is incorporated back in 1990 and headquartered in Hyderabad, Telangana, India. This company, at its initial stage of the foundation, was named as Divi's Research Centre and later on in 1994 was changed to Divi's Laboratories Limited. This company is responsible for manufacturing and selling APIs or active pharmaceutical ingredients along with intermediates for generics. This is carried on in India, other parts of Asia, US, Europe and several other parts of the world.
    It offers the different unit for building compounds like several carotenoids inclusive of beta-carotene, astaxanthin, canthaxanthin, lycopene, and apocarotenol. Other than this it also offers groups for building protects amino acids like FMOC, BCZ and BOC as well as for chiral ligands and peptide and nucleotides.
    Apart from this, it also customizes the synthesis of several active pharmaceutical ingredients along with advanced forms of discovered compounds for other pharmaceutical companies. It also offers full-time contract-based research on development processes to identify new compounds.
    Company Information:
    Between the years 1991-1993, Divi's developed multiple bulk actives and other intermediates products for several other manufacturing companies. It received its ISO-9002 certification with compliance to SGS-Yarsley belonging to the UK, back in 1997. With the following two years, in 1999, the company received a Certificate of Suitability from the European Directorate for the production of Naproxen.
    For the company's system of occupational health and safety management, it received the OHSAS-18001 certificate. It was given to them by BVQI from London in 2001. In the year 2002, Divi's set up their Unit number II, a manufacturing facility in Chippada. In the following year in 2003, the company inaugurated a new research centre in Vizag, named DRC-Vizag. This was built for fundamental research in specific core segments.
    In the year 2004, Rs 3035.21 lakh was invested by Divi's for adding machines to both of their units in Unit-I (Choutuppal) and Unit-II (Chippada), and this was accounted for in their capital expenditure. In 2006, it received an approval letter from the Ministry of Commerce in India. This was for setting up a Special Economic Zone for multiple pharma based ingredients at Chippada, Vizag which led the company to invest Rs 200 crore.
    During the year 2008-09, the company's portfolio added a total of 9 products. Four of these nine products consisted of generic APIs, and the rest belonged to intermediates and custom synthesis of APIs. Another seven products were added to the company portfolio in 2009-2010. Out of these seven products, 2 were generic APIs along with intermediates, while the rests were intermediates and custom synthesis APIs. During the year 2012-13, the company went on to add another nine products out of which three of these were generic APIs along with intermediates, and the rest six were custom synthesis APIs and intermediates.
    On 19 February 2016, the company went through an inspection by US-FDA for its second unit in Chapada, Bhemunipatam near Vizag and was this event was successful which happened without any observation. In 2017, on 18 November, the company announced that it had received EIR (Establishment Inspection Report) from FDA (US) for their second unit in Vizag. On 16 May 2018, Divi's Laboratories stated that their Unit-I in Telangana was under the inspection of the US-FDA starting from 14 May 2018 to 16 May 2018. The review conducted was a cGMP general inspection done by the FDA.
    The company is one of the biggest pharmaceutical companies in the country, which currently has a portfolio of 120 products. It has presently products belonging to multiple therapeutic aspects. It has a total of four manufacturing units with a developing market presence in several countries. Their first facility is located in Yadadri Bhuvanagiri District; Telangana consists of 11 blocks for multipurpose production along with finishes product spaces for APIs.
    How Divi’s Laboratories, is categorised as a Pharmaceutical and Health care Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Divi's Laboratories is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Divi’s Laboratories, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.